Paul Dash, MD
Neurology · Baltimore, MDNPI 1942237987
Payments from drug & device makers
Across 334 payments — averaging $63.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$13K
- AbbVie$1K
- Lilly USA, LLC$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Amgen$942
- Lundbeck LLC$568
- plus $3K from 27 others
What the payments were for
- Consulting fees$9304%
- Speaking & faculty fees$11,62555%
- Food & beverage$8,25239%
- Education$3722%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 21 | $12,982 |
| AbbVie(2 entities) | 64 | $1,429 |
| Lilly USA, LLC | 54 | $1,257 |
| Teva Pharmaceuticals USA, Inc. | 32 | $1,165 |
| Amgen | 23 | $942 |
| Lundbeck LLC | 27 | $568 |
| Eisai Inc. | 10 | $371 |
| Impel Pharmaceuticals Inc. | 12 | $272 |
| Pfizer | 12 | $242 |
| Novartis | 16 | $241 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $234 |
| UCB, Inc. | 4 | $208 |
| Genentech USA, Inc. | 3 | $157 |
| AstraZeneca | 2 | $152 |
| Bristol Myers Squibb | 7 | $128 |
| SK Life Science, Inc. | 6 | $113 |
| Avanir Pharmaceuticals, Inc. | 5 | $102 |
| EMD Serono, Inc. | 4 | $88 |
| Amneal Pharmaceuticals LLC | 4 | $80 |
| Biohaven Pharmaceuticals, Inc. | 1 | $71 |
| Banner Life Sciences, LLC | 4 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Scilex Pharmaceuticals Inc. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Kyowa Kirin, Inc. | 1 | $22 |
| Upsher-smith Laboratories LLC | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $21 |
| TG Therapeutics, Inc. | 1 | $21 |
| Sanofi | 1 | $19 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$21,180 in reported general payments places this provider in the 75th percentile of 442 neurology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 88 | $86,727 |
| Nurtec OdtRimegepant Sulfate | 41 | $52,595 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $48,099 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 28 | $35,931 |
| QuliptaAtogepant | 26 | $27,555 |
| ZavzpretZavegepant Hcl | 11 | $11,855 |
| Gabapentin | 96 | $2,638 |
| Sumatriptan Succinate | 68 | $2,517 |
| Entacapone | 17 | $2,285 |
| RizatriptanRizatriptan Benzoate | 120 | $1,506 |
| Levetiracetam | 37 | $1,291 |
| Pregabalin | 19 | $1,031 |
| Divalproex Sodium | 20 | $937 |
| Donepezil Hcl | 68 | $841 |
| Topiramate | 36 | $698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt, Zavzpret | $242 | $64,45052 claims |
| AbbVieQulipta | $1,429 | $27,55526 claims |
| Upsher-smith Laboratories LLCTopiramate | $22 | $69836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 442 neurology providers in Maryland.
Other neurology in Baltimore
- Ellen MowryBaltimore$5.7M
- Michael PolydefkisBaltimore$4.1M
- Jeffrey RothsteinBaltimore$3M
- Pavan BhargavaBaltimore$2.8M
- Thomas CrawfordBaltimore$2.4M
- Nicholas MaragakisBaltimore$2.2M
- Shiv SaidhaBaltimore$2.1M
- Karisa SchreckBaltimore$1.9M
- Scott NewsomeBaltimore$1.7M
- Kathryn WagnerBaltimore$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.